The update interpretation of 2020 EAU prostate cancer guideline(Part Ⅴ)
10.3760/cma.j.cn112330-20200525-00009
- VernacularTitle:2020版EAU前列腺癌指南更新解读之五
- Author:
Hao LIU
1
;
Tianxin LIN
Author Information
1. 中山大学孙逸仙纪念医院泌尿外科，广州 510120
- From:
Chinese Journal of Urology
2020;41(6):412-414
- CountryChina
- Language:Chinese
-
Abstract:
EAU Guideline office updated the 2020 version of prostate cancer guideline based on novel clinical evidence. In the section of metastatic hormone sensitive prostate cancer (mHSPC), the 2020 EAU guideline introduced and strongly recommended the use of second-generation androgen receptor antagonists in combination with androgen deprivation therapy (ADT), the recommendation level of prostate radiotherapy combined with ADT to low-volume patients changed from weak to strong, and the intermittent ADT is no longer included in the recommendation.
